Possible epigenetic regulatory effect of dysregulated circular RNAs in Alzheimer's disease model

被引:19
|
作者
Lee, Woo-Jin [1 ,2 ]
Moon, Jangsup [1 ,2 ]
Jeon, Daejong [3 ]
Shin, Yong-Won [1 ,2 ]
Yoo, Jung-Suk [1 ]
Park, Dong-Kyu [1 ]
Lee, Soon-Tae [1 ,2 ]
Jung, Keun-Hwa [1 ,2 ]
Park, Kyung-Il [1 ,2 ,4 ]
Jung, Ki-Young [1 ,2 ]
Kim, Manho [1 ,2 ]
Lee, Sang Kun [1 ,2 ]
Chu, Kon [1 ,2 ]
机构
[1] Seoul Natl Univ Hosp, Biomed Res Inst, Dept Neurol, Comprehens Epilepsy Ctr,Lab Neurotherapeut, Seoul, South Korea
[2] Seoul Natl Univ, Neurosci Res Inst SNUMRC, Coll Med, Program Neurosci, Seoul, South Korea
[3] Adv Neural Technol, Seoul, South Korea
[4] Seoul Natl Univ, Healthcare Syst Gangnam Ctr, Dept Neurol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
AMYLOID-BETA; MICRORNAS; BRAIN; EXPRESSION; IDENTIFICATION; BIOMARKERS; PATHWAYS; NETWORK;
D O I
10.1038/s41598-019-48471-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
As circular RNAs (circRNAs) regulates the effect of micro RNAs (miRNAs), circRNA-miRNA-mRNA network might be implicated in various disease pathogenesis. Therefore, we evaluated the dysregulated circRNAs in the Tg2576 mouse Alzheimer's disease (AD) model, their possible regulatory effects on downstream target mRNAs, and their pathomechanistic role during the disease progression. The microarray-based circRNA expression analysis at seven-and twelve-months of ages (7 M and 12 M) returned 101 dysregulated circRNAs at 7 M (55 up-regulated and 46 down-regulated) and twelve dysregulated circRNAs at 12 M (five up-regulated and seven down-regulated). For each dysregulated circRNA, potential target miRNAs and their downstream target mRNAs were searched. Dysregulation of circRNAs was associated with increased frequency of relevant dysregulation of their downstream target mRNAs. Those differentially expressed circRNA-miRNA-mRNA regulatory network included 2,275 networks (876 for up-regulated circRNAs and 1,399 for down-regulated circRNAs) at 7 M and 38 networks (25 for up-regulated circRNAs and 13 for down-regulated circRNAs) at 12 M. Gene ontology (GO) and pathway analyses demonstrated that the dysregulated mRNAs in those networks represent the AD pathomechanism at each disease stage. We concluded that the dysregulated circRNAs might involve in the AD pathogenesis by modulating disease relevant mRNAs via circRNA-miRNA-mRNA regulatory networks.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Screening of Human Circular RNAs as Biomarkers for Early Onset Detection of Alzheimer's Disease
    Zheng, Da
    Tahir, Rana Adnan
    Yan, Yan
    Zhao, Juan
    Quan, Zhenzhen
    Kang, Guixia
    Han, Ying
    Qing, Hong
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [22] Noncoding RNAs in Alzheimer's disease
    Idda, M. Laura
    Munk, Rachel
    Abdelmohsen, Kotb
    Gorospe, Myriam
    WILEY INTERDISCIPLINARY REVIEWS-RNA, 2018, 9 (02)
  • [23] The epigenetic landscape of Alzheimer's disease
    Jenny Lord
    Carlos Cruchaga
    Nature Neuroscience, 2014, 17 : 1138 - 1140
  • [24] Epigenetic Alterations in Alzheimer's Disease
    Sanchez-Mut, Josev.
    Graeff, Johannes
    FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2015, 9
  • [25] The epigenetic landscape of Alzheimer's disease
    Lord, Jenny
    Cruchaga, Carlos
    NATURE NEUROSCIENCE, 2014, 17 (09) : 1138 - 1140
  • [26] Epigenetic mechanisms in Alzheimer's disease
    Mastroeni, Diego
    Grover, Andrew
    Delvaux, Elaine
    Whiteside, Charisse
    Coleman, Paul D.
    Rogers, Joseph
    NEUROBIOLOGY OF AGING, 2011, 32 (07) : 1161 - 1180
  • [27] Epigenetic Mechanisms in Alzheimer's Disease
    Daniilidou, M.
    Koutroumani, M.
    Tsolaki, M.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (12) : 1751 - 1756
  • [28] Epigenetic mechanisms in Alzheimer's disease
    Balazs, Robert
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2014, 4 : 85 - 102
  • [29] Alzheimer's disease and epigenetic diet
    Sezgin, Zeynep
    Dincer, Yildiz
    NEUROCHEMISTRY INTERNATIONAL, 2014, 78 : 105 - 116
  • [30] Epigenetic drugs for Alzheimer's disease
    Peedicayil, Jacob
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (04) : 1152 - 1153